Cantor Fitzgerald Reaffirms Overweight Rating for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a research note issued on Tuesday, Benzinga reports. They presently have a $36.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 389.13% from the stock’s current price.

Separately, StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $7.36 on Tuesday. Abeona Therapeutics has a 1 year low of $2.83 and a 1 year high of $9.01. The stock has a market cap of $201.30 million, a PE ratio of -2.85 and a beta of 1.49. The business’s fifty day moving average is $7.49 and its 200-day moving average is $5.65.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.13). Equities research analysts predict that Abeona Therapeutics will post -1.83 earnings per share for the current year.

Institutional Trading of Abeona Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Jump Financial LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter worth $199,000. Worth Venture Partners LLC boosted its position in shares of Abeona Therapeutics by 76.6% in the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after buying an additional 121,969 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in shares of Abeona Therapeutics by 84.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock worth $13,682,000 after buying an additional 1,488,834 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter worth $648,000. Finally, AIGH Capital Management LLC boosted its position in shares of Abeona Therapeutics by 77.7% in the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after buying an additional 496,278 shares during the period. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.